-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Verdiperstat in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Verdiperstat in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Verdiperstat in Amyotrophic Lateral Sclerosis Drug Details: Verdiperstat (AZD-3241) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Felzartamab in Antibody-Mediated Rejection (AMR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Felzartamab in Antibody-Mediated Rejection (AMR) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Felzartamab in Antibody-Mediated Rejection (AMR) Drug Details: Felzartamab is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRG-002 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRG-002 in...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – INBRX-106 in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INBRX-106 in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INBRX-106 in Nasopharyngeal Cancer Drug Details: INBRX-106 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AT-101 in Neuroendocrine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AT-101 in Neuroendocrine Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AT-101 in Neuroendocrine Cancer Drug Details: AT-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKG2D CAR-NK in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKG2D CAR-NK in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKG2D CAR-NK in Epithelial Ovarian Cancer Drug Details: Gene-modified cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XB-002 in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XB-002 in Oropharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XB-002 in Oropharyngeal Cancer Drug Details: XB-002 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XB-002 in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XB-002 in Oral Cavity (Mouth) Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XB-002 in Oral Cavity (Mouth) Cancer Drug Details: XB-002...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nogapendekin Alfa in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nogapendekin Alfa in Peritoneal Cancer Drug Details: Nogapendekin alfa (ALT-803)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Duvelisib in Splenic Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Duvelisib in Splenic Marginal Zone B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Duvelisib in Splenic Marginal Zone B-Cell Lymphoma Drug Details:...